S1

Shanghai Pharmaceuticals Holding Co LtdFRA Shanghai Pharmaceuticals Stock Report

Last reporting period 31 Dec, 2023

Updated —

Last price

Market cap $B

7.595

Middle

Exchange

XFRA - Deutsche Boerse AG

S1R.F Stock Analysis

S1

Avoid

Based on Eyestock quantitative analysis, S1R.F`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

18/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-37.7 %

Greatly overvalued

Market cap $B

7.595

Dividend yield

2.65 %

Shares outstanding

3 698.06 B

Shanghai Pharmaceuticals Holding Co Ltd is a CN-based company operating in Health Care Providers & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 47,056 full-time employees. Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The firm's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The firm's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The firm distributes its products both in the domestic market and to overseas markets.

View Section: Eyestock Rating